Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

Understanding Sickle Cell Anemia and the Need for Early DiagnosisSickle cell anemia is a genetic blood disorder caused by a ...

Gallbladder problems are a common complication in individuals with sickle cell disease. These issues often arise due to the breakdown of red blood cells and the subsequent formation of gallstones ...

Opens in a new tab or window The development and approval of gene therapies has been a potential game changer for patients with beta-thalassaemia who have been dependent on regular red blood cell ...

Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with ...

A GROUNDBREAKING gene-editing treatment for sickle cell disease has been approved for use in the UK by the NHS, offering the potential for a cure. Known as exagamglogene autotemcel (exa-cel), this one ...

Sickle cell anaemia is caused by a mutation in the HBB gene, which provides instructions for making the beta-globin subunit of haemoglobin. The disorder follows an autosomal recessive inheritance ...

A gene regulatory network is a set of genes, or parts of genes, that interact with each other to control a specific cell function. Gene regulatory networks are important in development ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...